Anemias

A current meta-analysis of HIF-PHIs showed that these drugs improve the response rate of hemoglobin and decrease hepcidin levels.

In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy.

Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.

Although the association between thrombocytosis in iron deficiency anemia is understood, researchers studied the risk for thrombotic complications.

Transferrin saturation and ferritin concentrations improved significantly more in the ferric citrate than ferrous sulfate group over 12 weeks.

Low hemoglobin levels in patients with IgAN increase their risk for end-stage kidney disease, according to new research.

In a phase 3 trial, mean hemoglobin was maintained within target range during 52 weeks of treatment with oral daprodustat.

Investigators found sex and racial differences in the risk for end-stage kidney disease among patients with CKD anemia.

In a study, older hemodialysis patients performing resistance exercise for 24 weeks saw their iron bioavailability increase.

For patients with chronic kidney disease (CKD) receiving erythropoiesis-stimulating agents (ESAs), achieving hemoglobin (Hb) levels higher than guideline-recommended target range is associated with a small but potentially clinically significant improvement in fatigue, although not in the ability to perform usual daily work or other activities. In a systematic review and meta-analysis of 15 randomized trials…